Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers.
Authors
Yap, TKrebs, Matthew G
Postel-Vinay, S
Bang, Y
El-Khoueiry, A
Abida, W
Harrington, K
Sundar, R
Carter, Louise
Castanon-Alvarez, E
Im, S
Berges, A
Khan, M
Stephens, C
Ross, G
Soria, J
Affiliation
Royal Marsden Hospital and the Institute of Cancer Research, LondonIssue Date
2016-12
Metadata
Show full item recordCitation
Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. 2016, 69(Suppl 1):S2 European Journal of CancerJournal
European Journal of CancerDOI
10.1016/S0959-8049(16)32607-7Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0959804916326077Type
Meetings and ProceedingsLanguage
enISSN
09598049ae974a485f413a2113503eed53cd6c53
10.1016/S0959-8049(16)32607-7